David Millan

Chief Scientific Officer @Auron Therapeutics, Inc

Newton, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Dec 2021 — Present

Chief Scientific Officer @Auron Therapeutics, Inc

View department →

Newton, MA, US

Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN™ platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors.

EDUCATION

1992 — 1995

Flinders University

Bachelor of Science (Hons), Chemistry with Molecular Biology and Biochemistry

1996 — 1999

Flinders University

PhD, Synthetic Organic Chemistry

SKILLS

Leading MeetingsProject ManagementPharmacokineticsDrug DeliveryLead ChangeDrug DiscoveryOrganic SynthesisLead OptimisationClinical TrialsOrganic ChemistryLeadershipAdmeBiotechnologyMentoringCommunicationIn Vitro ToxicologyDrug MetabolismDrug DesignChemistryLife SciencesPharmaceutical IndustryDrug SafetyLead GenerationCancer ResearchProtein KinasesWritten & Oral Presentation SkillsMedicinal ChemistryScienceRespiratory TherapyPharmaceutical SciencesSynthetic Organic ChemistryTeam LeadershipDmpk

ABOUT DAVID MILLAN

An accomplished and entrepreneurial drug discovery leader with 25 years of scientific and operational leadership experience spanning privately funded Biotech start-ups through to mid- and large cap Pharma. Therapeutic area experience includes oncology/ IO, respiratory, metabolic diseases, inflammation, & neuro/ pain. Played key roles in the discovery of 10+ first-in-class development candidates, with several progressing to Phase 2 clinical development. Expertise developed in a diversity of target classes, drugging modalities and technologies, through all stages of the drug discovery continuum. A confident leader and communicator that can develop and articulate vision. Significant experience of building, developing and motivating teams to achieve challenging goals. Driven by a deep curiosity and passion for the intersection of human disease, new therapy development and value creation.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.